CNTN Overview

Canton Strategic Holdings, Inc., formerly Tharimmune, Inc., is advancing institutional blockchain adoption to drive the digitization of financial markets. In addition to driving value through activities on the Canton Network, the Company operates a Super Validator, ensuring safe and secure transactions across the Network. The Company also operates a clinical-stage biotech research and development arm. Its lead clinical asset, GV104, is being developed for a specific indication via a 505(b)2 pathway for respiratory and/or nervous system depression in military personnel and chemical incident responders who may encounter high-potency opioids. The expanded pipeline includes other indications for GV104 and GV023, a new approach to autoimmune diseases, as well as an early-stage multispecific biologic platform.

Wall Street analysts forecast CNTN stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for CNTN is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Canton Strategic Holdings Inc revenue for the last quarter amounts to -13.62M USD, increased 253.86

Canton Strategic Holdings Inc. EPS for the last quarter amounts to USD, decreased

Canton Strategic Holdings Inc (CNTN) has 12 emplpoyees as of May 13 2026.

Today CNTN has the market capitalization of 185.27M USD.